Evidence map›Paper›PMID 37595069›Full record

ArticleAge and ageing2023

Effectiveness of successive booster vaccine doses against SARS-CoV-2 related mortality in residents of long-term care facilities in the VIVALDI study.

Oliver Stirrup, Madhumita Shrotri, Natalie L Adams, Maria Krutikov, Borscha Azmi, Igor Monakhov, Gokhan Tut, Paul Moss, Andrew Hayward, Andrew Copas and 1 more

Open access · hybridAbstract readEvaluation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Age and ageing, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Oliver StirrupInstitute for Global Health, University College London, London, UK.ORCID 0000-0002-8705-3281
Madhumita ShrotriUCL Institute of Health Informatics, University College London, London, UK.
Natalie L AdamsUCL Institute of Health Informatics, University College London, London, UK.
Maria KrutikovUCL Institute of Health Informatics, University College London, London, UK.ORCID 0000-0002-3982-642X
Borscha AzmiUCL Institute of Health Informatics, University College London, London, UK.
Igor MonakhovUK Health Security Agency, London, UK.
Gokhan TutInstitute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
Paul MossInstitute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
Andrew HaywardUCL Institute of Epidemiology & Healthcare, University College London, London, UK.
Andrew CopasInstitute for Global Health, University College London, London, UK.
Laura ShallcrossUCL Institute of Health Informatics, University College London, London, UK.
Farr Institute · GBNIHR Birmingham Biomedical Research Centre · GBThe George Institute for Global Health · GBUK Health Security Agency · GBUniversity College Hospital · GB

Funding

Chief Scientist OfficeDepartment of Health CS-2016-007Medical Research CouncilWellcome TrustWellcome Trust 222907/Z/21/Z
6 · The paper itself

Abstract

backgroundSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused severe disease in unvaccinated long-term care facility (LTCF) residents. Initial booster vaccination following primary vaccination is known to provide strong short-term protection, but data are limited on duration of protection and the protective effect of further booster vaccinations.

objectiveTo evaluate the effectiveness of third, fourth and fifth dose booster vaccination against SARS-CoV-2 related mortality amongst older residents of LTCFs.

designProspective cohort study.

settingLTCFs for older people in England participating in the VIVALDI study.

methodsResidents aged >65 years at participating LTCFs were eligible for inclusion if they had at least one polymerase chain reaction or lateral flow device result within the analysis period 1 January 2022 to 31 December 2022. We excluded individuals who had not received at least two vaccine doses before the analysis period. Cox regression was used to estimate relative hazards of SARS-CoV-2 related mortality following 1-3 booster vaccinations compared with primary vaccination, stratified by previous SARS-CoV-2 infection and adjusting for age, sex and LTCF size (total beds).

resultsA total of 13,407 residents were included. Our results indicate that third, fourth and fifth dose booster vaccination provide additional short-term protection against SARS-CoV-2 related mortality relative to primary vaccination, with consistent stabilisation beyond 112 days to 45-75% reduction in risk relative to primary vaccination.

conclusionsSuccessive booster vaccination doses provide additional short-term protection against SARS-CoV-2 related mortality amongst older LTCF residents. However, we did not find evidence of a longer-term reduction in risk beyond that provided by initial booster vaccination.

Indexed as

COVID-19COVID-19 VaccinesSARS-CoV-2AgedEnglandHumansImmunization, SecondaryLong-Term CareProspective StudiesSkilled Nursing FacilitiesVaccine EfficacyCOVID-19 VaccinesCOVID-19long-term care facilitiesolder peopleomicronSARS-CoV-2vaccine effectiveness

Identifiers

PMID37595069
PMCPMC10438206
OpenAlexW4385972723

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.